Hot Products
| Catalog No. | Information |
| CFN98780 | Robinetin Robinetin has antioxidant and antiradical activities, inhibits EYPC membrane lipid peroxidation and HbA glycosylation with high efficiency. Robinetin also has anti-mutagenesis and anti-promotion effects, diminishes ornithine decarboxylase activity induction at 6 h after 12-O-tetradecanoyl phorbol-13-acetate. Robinetin leads to the occurrence of positive induced circular dichroism (ICD) bands in the near ultra-violet (UV) region. |
| CFN98375 | Robinin Robinin has cardioprotective effect on doxorubicin-induced cardiac toxicity by modulating TGF-β1 signaling pathway in Sprague Dawley rats. Robinin has protective effect against the ox-LDL induced inflammation stress in hPBMCs by inhibiting TLR4-NF-κB signaling pathway. |
| CFN97767 | Robtein Reference standards. |
| CFN98672 | Robtin Reference standards. |
| CFN98562 | Roburic acid Roburic acid and phenethyl-trans-ferulate inhibit COX-1 and COX-2. |
| CFN96362 | Robustine Robustine may have anti-inflammatory activity, it exhibits inhibition (IC 50 < or = 18.19 microM) of superoxide anion generation by human neutrophils in response to formyl- l-methionyl- l-leucyl- l-phenylalanine/cytochalasin B (FMLP/CB). |
| CFN97339 | Rocaglamide Rocaglamides are potent natural anticancer products that inhibit proliferation of various cancer cells at nanomolar concentrations, it prevents tumor growth and sensitize resistant cancer cells to apoptosis by blocking the MEK-ERK-eIF4 pathway. Rocaglamides can suppress the PMA-induced expression of NF-kappaB target genes and sensitize leukemic T cells to apoptosis induced by TNFalpha, cisplatin, and gamma-irradiation, suggests that rocaglamide derivatives could serve as lead structures in the development of anti-inflammatory and tumoricidal drugs. Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas. |
| CFN99609 | Rocaglaol Rocaglaol is a potent anticancer drug that induces apoptosis of LNCaP cells through the mitochondrial pathway and its G2/M-phase cell cycle arrest is associated with the down-regulation of Cdc25C and the dephosphorylation of Cdc2. Rocaglaol can reduce tissue inflammation and neuronal cell death by inhibiting NF-kappa B and AP-1 signaling, resulting in significant neuroprotection in animal models of neurodegeneration. Rocaglaol derivatives can prevent or to limit the cardiotoxicity of an antineoplastic agent, in particular to prevent or to limit the apoptosis of cardiomyocytes induced by such agent. Rocaglaol, pyrimidinone and aglaiastatin are potent inhibitors of the growth of K--cells, with IC50 values of 1-10 ng/mL, and induce normal morphology in K--cells at 10-30 ng/mL, they also specifically inhibit protein synthesis. |
| CFN91019 | Roemerine Roemerine is a potential active xanthine oxidase(XOD) inhibitor, XOD is a key enzyme in the pathogenesis of hyperuricemia and also a well-known target for the drug development to treat gout. Roemerine has some anti-prostate cancer effect and alleviates adverse reactions in paclitaxel combination administration. Roemerine shows significant anti-plasmodial activities with IC(50) ranged from 1.2 μM to 52.3 uM. Roemerine also possesses antibacterial activity, it improves the survival rate of septicemic BALB/c mice by increasing the cell membrane permeability of Staphylococcus aureus. |
| CFN90020 | Roflumilast Roflumilast is a phosphodiesterase 4 inhibitor that may improve lung function and reduce the frequency of exacerbations in patients with COPD. Roflumilast has anti-inflammatory and immunomodulatory potential,it will be useful in the treatment of chronic inflammatory disorders such as asthma and chronic obstructive pulmonary disease. Suppression of hematological and immunological markers of inflammation and enhanced apoptosis in animals treated with Roflumilast points to the possibility of a beneficial effect of Roflumilast in allergic inflammation. |
